Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Dec 7;207(5):740–748. doi: 10.1093/infdis/jis750

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2012. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — Study design. Subjects received dolutegravir (DTG) 50 mg once daily (cohort I) or DTG 50 mg twice daily (cohort II). In both cohorts, subjects were allocated to 1 of 2 groups on the basis of integrase genotype at screening, to ensure a broad representation of genotypes and a range of phenotypic susceptibility. Cohort II subjects were required to have ≥1 fully active antiretroviral therapy in an optimized background regimen (OBR). Abbreviation: RAL, raltegravir. ^aQ148H/K/R plus changes in L74, E138, or G140. ^bSubjects remained on failing background regimen from day 1 to day 10.